abstract |
The present invention relates to prodrugs of 3 - ({3- (4-chlorophenyl) -5-oxo-4 - [(2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H 1,2,4-triazol-1-ylmethyl) -1- [3- (trifluoromethyl) -pyridin-2-yl] -1H-1,2,4-triazole-5-carboxamide, 3 - (3) (4-Chlorophenyl) -5-oxo-4 - [(2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H-1,2,4-triazol-1-yl } methyl) -1- [2- (trifluoromethyl) phenyl] -1H-1,2,4-triazole-5-carboxamide and 3 - ({3- (4-chlorophenyl) -5-oxo-4 - [( 2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H-1,2,4-triazol-1-yl} methyl) -1- (3-chloropyridin-2-yl) -1H-1,2,4-triazole-5-carboxamide, processes for the preparation of such compounds, pharmaceutical compositions containing such compounds, and the use of such compounds or compositions for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of renal and cardiovascular diseases. |